Delivery Order SPE2DB22D3501-SPE2DB24FTW23
- Not listed
- This federal contract award, valued at $52,896.76, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical company Amerisourcebergen Corporation. The contract is a firm fixed price delivery order for the supply of REVLIMID 25 MG CAPSULE 100S, a pharmaceutical product. The award does not have a set-aside designation. Amerisourcebergen Drug Corp is the prime contractor on an indefinite delivery contract (IDC) with DLA, valued at up...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is a firm fixed price delivery order for the supply of REVLIMID 10 MG Capsules. The award has a ceiling value of $105,612.88 and an ultimate completion date of May 3, 2024. Amerisourcebergen Drug Corp is the prime contractor and there is no set-aside...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $74,890.20, is a Firm Fixed Price Delivery Order for the supply of REVLIMID 10 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of January 24, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $178,310.12, is a Firm Fixed Price Delivery Order for the supply of REVLIMID 10 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of April 11, 2025 and was awarded on March 21, 2025. The contract is not designated with a set-aside requirement, indicating open...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of REVLIMID 25 MG CAPSULE 21S. The delivery order contract, valued at $18,722.57, is a firm fixed-price arrangement with an ultimate completion date of August 22, 2024. Amerisourcebergen, through its Corporate Office division, will provide these pharmaceutical products to support the healthcare needs of federal agencies and their...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $24,963.40 firm fixed-price delivery order is for the supply of REVLIMID 5 MG CAPSULE 28S, a pharmaceutical product. The contract has an ultimate completion date of March 11, 2025 and was awarded on February 18, 2025. This appears to be a task order under a larger Indefinite Delivery Contract (IDC) that...
- This federal contract award, valued at $89,155.06, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for 4,567,951,671 units of the medication REVLIMID 25 MG CAPSULE 100S, with a performance period through May 7, 2025. The contract is a firm fixed-price, non-set-aside award. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery...
- This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The award is a firm fixed price delivery order for the supply of REVLIMID 25 MG CAPSULE 100S, a pharmaceutical product, with a potential value of $107,931.18. The contract has a completion date of March 20, 2023. No set-aside designation was used. Amerisourcebergen Drug...
- This is a firm fixed price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation, a leading global pharmaceutical sourcing and distribution services company. The contract is to provide REVLIMID 25 MG CAPSULE 100S, a pharmaceutical product, with a potential value of $107,931.18. The contract has a completion date of June 16, 2023. Amerisourcebergen Drug Corp has received numerous federal contract...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,722.57 firm-fixed-price delivery order is for the supply of REVLIMID 25 MG CAPSULE 21S, a specialty pharmaceutical product. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for...
- SPE2DB22D3501Indefinite Delivery Contract
- SPE2DB22D3501-SPE2DB24FTW23Delivery Order
This federal contract award, valued at $28,471.12, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Amerisourcebergen Corporation. The contract is for the delivery of REVLIMID 5 MG CAPSULE 28S, a pharmaceutical product, with a completion date of January 8, 2024. This is a firm fixed price delivery order contract, with no set-aside designation. Amerisourcebergen Drug Corp is an established prime contractor providing a wide range of pharmaceutical products and medical supplies to U.S. government agencies, particularly the Department of Defense, through various indefinite delivery contract vehicles. This award represents one such task order for the provision of specialty medications in support of military treatment programs and facilities.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $28.5k | 12/14/23 |